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ABSTRACT
Objective: To evaluate the metabolic control of a cohort of adult type 1
diabetes mellitus (T1DM) patients assisted in a public Diabetes Center
(DC) that follows the rules of a national diabetes society. Methods: We
compared for one year the metabolic control and the characteristics of
175 T1DM patients attended by a multidisciplinary team in a DC (test
group) with 30 patients assisted only by endocrinologists at a public
endocrinology outpatient center (control group). Results: The test group
presented a larger proportion of well-controlled patients (p= 0.002). The
proportions (test x control group) were as follows: 51.4% x 16.7% in the
subgroup with A1C < 7%; 21.7% x 36.7% in the subgroup with A1C
between 7.1% and 8.0%; and 26.9% x 46.7% in the subgroup with A1C >
8%. Patients assisted in the DC presented a likelihood 4.38 times higher of
reaching levels of A1C up to 7%. Conclusions: This study shows the effec-
tiveness of a DC and emphasizes the importance of education, adher-
ence and multidisciplinarity as cornerstones for the treatment, showing
that in developing countries it is possible to treat T1DM with satisfactory
results. (Arq Bras Endocrinol Metab 2006;50/5:944-950)
Keywords: Diabetes mellitus, type 1; Insulin; Health services; Patient edu-
cation; Brazil.
RESUMO
Controle Glicêmico em Pacientes Adultos com Diabetes do Tipo 1 em
Uma Cidade Brasileira: Comparação entre Abordagem Multidisciplinar e
Endocrinológica de Rotina.
Objetivo: Avaliar o controle metabólico de uma coorte de pacientes
adultos com diabetes do tipo 1 (DM1) atendidos em um Centro de
Diabetes (CD) que segue as normas da Sociedade Brasileira de
Diabetes. Métodos: Foram comparados o controle glicêmico e as
características de 175 pacientes com DM1 atendidos por uma equipe
multidisciplinar em um CD (grupo teste) com 30 pacientes assistidos em
um ambulatório de endocrinologia geral (grupo controle) durante um
ano. Resultados: O grupo teste apresentou uma maior proporção de
pacientes bem controlados (p= 0,002). As proporções (grupo teste x
grupo controle) foram: 51,4% x 16,7% no subgrupo com A1C < 7%; 21,7%
x 36,7% no subgrupo com A1C entre 7,1% e 8,0%; e 26,9% x 46,7% no
subgrupo com A1C > 8%. Os pacientes atendidos no CD apresentaram
probabilidade 4,38 vezes maior de atingir níveis de A1C até 7%.
Conclusão: O estudo mostra a efetividade do CD e enfatiza a
importância da educação, aderência e da multidisciplinaridade como
pedras angulares do tratamento, mostrando ser possível tratar o DM1
nos países em desenvolvimento com resultados satisfatórios. (Arq Bras
Endocrinol Metab 2006;50/5:944-950)
Descritores: Diabetes mellitus tipo 1; Insulina; Serviços de saúde;
Educação do paciente; Brasil
perspectivas
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TYPE 1 DIABETES MELLITUS (T1DM) corresponds toapproximately 10% of all the cases of diabetes and
affects between 10 and 20 million individuals world-
wide (1). In about 40% of the cases, T1DM appears
during the adult age, which begins, in general, less
dramatically and eventually can be confused with type
2 diabetes in lean patients (2).
The prevalence of T1DM varies among the
studied areas (3) and according to the International
Diabetes Federation (IDF) data, this disease is present
in approximately 0.11% of the general population of
South American countries (4).
Nowadays, it is well established that a great per-
centage of primary and secondary prevention of chron-
ic diabetes complications can be achieved with a good
glycemic control — levels of glycated hemoglobin
(A1C) up to 7% — as much in T1DM (5) as in type 2
diabetes mellitus (T2DM) (6), resulting in a reduction
of its morbi-mortality and costs (7-9). There are stud-
ies showing that in T1DM a significant increase of the
prevalence of microangiopathic complications occur
when A1C levels are higher than 8%, suggesting such
level to be the maximum accepted limit (10-12).
In developing countries, although DM represents
a serious public health concern, strict glycemic control is
difficult to achieve, owing to financial constraints, cul-
tural obstacles, and lack of adequate infrastructure
underlying public services. However, it is known that
even in developed countries (13) the goal of reaching an
ideal glycemic control is still a great challenge.
In Brazil, the Ministry of Health has been
implementing programs to reduce DM impact on the
population’s health and the national budget. One of
the strategies adopted was to stimulate and to imple-
ment the creation of Diabetes Centers (DC), where
patients are accepted to be cared for by a multidisci-
plinary team and receive enough insulin vials until the
next consultation. Conversely, the continuous supply
of insulin is still a critical point in many developing
countries (14).
Such Brazilian Diabetes Society guidelines
began to be implemented more than a decade ago, but
so far, its impact on the glycemic control of DM
patients has not been evaluated.
Considering that the adult’s T1DM, in spite of
being characterized for an insulinopenic state (as in
T1DM in the youth), has a more stable behavior (2),
and taking into account the complexity of the T2DM
treatment (the approach to insulin secretion alteration,
insulin resistance, arterial hypertension and dyslipi-
demia that frequently occur in those patients), we sup-
posed that T1DM in the adult would be a good model
for an initial evaluation of the impact of a DC on the
patients’ glycemic control.
So, the objective of this study was to evaluate
the glycemic control of a cohort of adult T1DM
patients, treated in a DC of a medium-sized city (Juiz
de Fora, Brazil), which follows the recommendations
of the Brazilian Diabetes Society, during a one-year
period (2003).
MATERIAL AND METHODS
Type 1 Diabetes Mellitus population studied
According to the Brazilian Diabetes Society calcula-
tion method, it is estimated that there are about 7,632
diagnosed diabetics in Juiz de Fora (approximately
763 Type 1 and 6,869 Type 2) out of a population of
439,716 inhabitants (15).
Description of the outpatient centers
The DC of the Public Health Office of Juiz de Fora
has a waiting room, five medical offices, a meeting
room with audiovisual system, an insulin storage
room, and offices for a social assistant, a nutritionist
and a head nurse/diabetes educator. In addition, there
is a pre-appointment room where the nurse checks
patient’s body weight, height, blood pressure, abdom-
inal circumference and capillary blood glucose. After
the doctor’s appointment, the patient receives the
insulin vials with a kit for application and the next con-
sultation is scheduled.
The DC patients benefit from the services of a
multidisciplinary team comprised of five endocrinolo-
gists, a nutritionist, a social assistant, three nurses, two
administrative auxiliaries, and a head nurse certified by
the Ministry of Health in diabetes education. When
the patient is admitted to DC or whenever a doctor
detects some situation that jeopardizes the treatment
compliance, the head nurse supplies information to
the patient about insulin use, diet, hypoglycemia, foot
care and lifestyle. The patients attend bimonthly meet-
ings with all the DC board, in groups of up to 10
patients, where the education strategies are focused
using audiovisual methods and discussion groups
about nutrition, exercise regimens and foot care,
among other topics. The consultations with each
member of the DC board last about 60 minutes.
The DC distributes about 4,000 NPH insulin
vials a month. At the DC, a great emphasis is placed
upon education and the necessity of bimonthly
appointment, which is a condition for the patient to
still receive continuous free insulin.
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Juiz de Fora City has also a public general
endocrinology center (EC), where, unlike the DC, any
kind of endocrinopathy is treated. At the EC only
endocrinologists attend the patients without a multi-
disciplinary approach.
Due to the fact that at both the DC and the EC
only NPH insulin is available, all patients are treated
with 1 or 2 daily applications of this kind of insulin
(fasting and bedtime). The DC and the EC do not
offer dipsticks for self-management (capillary glycemia
or glycosuria) and the patients’ metabolic control is
assessed according to A1C and fasting blood glucose
(FBG) levels.
Patients
One hundred and seventy five patient records of adult
T1DM patients who have received the whole multidis-
ciplinary support available in the DC were analyzed (test
group). The records of 30 adult T1DM patients in
attendance at the EC were taken as a control group.
T1DM was classified as the patients for whom the use
of insulin was necessary since the onset of the symptoms
in order to normalize the glycemic levels, in agreement
with the World Health Organization criteria (16).
Patients with T1DM were eligible for inclusion if
they were aged equal or above 20 years old at diagnosis
and had at least six consultations at the DC in 2003.
The patients from the EC have attended up to three
consultations during the same period. None of the stud-
ied patients had clinical signs of chronic complications.
The local ethics committee approved the study.
Methods
The annual (2003) average of the A1C (high perfor-
mance liquid chromatography, normal value up to 6%)
and fasting plasma glucose — FPG — (enzymatic col-
orimetric method, normal value: 70 to 100 mg/dl=
3.9 to 5.6 mmol/l) were calculated for each patient.
Aiming to assess glycemic control, all patients in
our study were divided into three subgroups according
to the A1C value: subgroup A (A1C up to 7%), sub-
group B (A1C between 7.1 and 8%) and subgroup C
(A1C higher than 8%).
Age and gender were analyzed along with DM
duration in years, age at the diabetes onset, mean body
mass index (BMI) in kg/m2, daily mean NPH insulin
dose in U/kg/day, number of daily insulin applica-
tions, patient compliance and acute complications
from the database.
In the present study, it was considered as a dietary
indiscretion the reported consumption of food with
sucrose at least three times a week (17), without includ-
ing the use of sweets consumed during hypoglycemic
episodes. It was considered as a drug misuse any omis-
sion in the insulin use reported by the patient (18).
To evaluate the occurrence of acute complica-
tions, only hypoglycemic episodes in which the patient
reported the classic symptoms followed by an
improvement after the ingestion of sweets were com-
puted, having been considered as serious the hypo-
glycemia that needed the help of others, or with loss
of consciousness (19). Ketoacidosis episodes were
computed after being confirmed by the hospital dis-
charge summary.
In order to compare the glycemic control
between the test (DC) and control (EC) groups, the
patients’ proportions were considered, in both groups,
according to the three subgroups of A1C.
Statistical analysis
Continuous variables are expressed as mean ± SD. The
categorical variables are expressed as proportions. The
comparison of means among the three subgroups was
analyzed through the one-way ANOVA, the differ-
ences between two means through the Student’s t-test
(double tail) and the differences among proportions
through the chi-square or Fisher’s exact test. A logis-
tic binary regression was performed in the whole sam-
ple (205 patients) in order to quantify the association
between the treatment center (DC or EC) and the
glycemic control (outcome), considering other vari-
ables that could affect the A1C levels. A p value less
than 5% was considered statistically significant. The
statistical package Minitab version 14.0 was used to
analyze the data.
RESULTS
Description of the test (DC) and control (EC)
groups
The test and the control groups were similar to each
other in relation to age, gender, time of DM diagno-
sis, age at clinical picture onset, BMI, number of daily
applications of insulin, mean daily dose of insulin, pro-
portion of reports of insulin misuse, and hypoglycemia
and ketoacidosis episodes. In the control group, there
were more reports of dietary indiscretions and the
daily amount of NPH insulin used was greater. The
means of the A1C and FPG were lower in the test
group, without any overlap between the 99% confi-
dence intervals. These results are summarized in table
1. The patients’ proportion with A1C > 7% that took
two applications was greater than those who took just
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one application in both the test group (p= 0.039) and
the control group (p= 0.041), as verified by the Fish-
er’s exact test.
Analysis of the test group (DC) according to
A1C values
The three subgroups (A, B and C) of the test group
were similar to each other regarding age, gender, time
of DM diagnosis, age of DM onset, mean daily dose of
NPH insulin, BMI, number of reports of dietary indis-
cretions and drug misuse, and number of hypo-
glycemia reports. In the subgroups with A1C > 7% (B
and C) the patients’ proportion that took 2 daily appli-
cations of NPH insulin was greater. The only three
ketoacidosis reports in the test group occurred in the
subgroup B. The mean values of A1C were the fol-
lowing: 6.0 ± 0.67% in the subgroup A, 7.51 ± 0.3%
in the subgroup B and 9.6 ± 1.15% in the subgroup C.
The results are shown in table 2.
Comparison of glycemic control (DC x EC)
Comparing the test group with the control group, the
former presented a higher proportion of well-con-
trolled patients (χ2= 12.45, df= 2, p= 0.002). The
proportions (test group x control group) were the fol-
lowing: 51.4% x 16.7% in subgroup A (A1C < 7%),
21.7% x 36.7% in subgroup B (A1C between 7.1% and
8.0%) and 26.9% x 46.7% in subgroup C (A1C > 8%),
as illustrated in figure1.
Impact of the DC approach
The logistic regression analysis performed had as a
dependent binary variable the groups with A1C up to
7% and A1C > 7%. The numeric independent vari-
ables were the patients’ age, time of DM diagnosis,
mean insulin daily dose, and number of daily insulin
applications. The independent binary variable was
the treatment center (DC x EC). The results showed
that age (p= 0.307), time from DM diagnosis (p=
0.801), daily insulin dose (p= 0.284) and number of
applications (p= 0.082) did not present significant
influence on the tested outcome (A1C up to 7% x
A1C > 7%). However, the center where the patient
was assisted was the factor of decisive influence (p=
0.006, positive coefficient of 1.48), showing that
patients assisted at the DC presented a likelihood
4.38 times higher of presenting levels of A1C up to
7% (OR= 4.38, 95% CI= 1.53 to 12.57, p= 0.006).
All the assumptions of the logistic regression analysis
were verified (Log-Likelihood test: p< 0.001) and
the model’s goodness-of-fit was confirmed by the
tests of Pearson (p= 0.415) and Hosmer-Lemeshow
(p= 0.108). The association measures were solid
(Goodman-Kruskal Gamma coefficient= 0.34) (20).
DISCUSSION
According to the estimated T1DM prevalence and the
population of the city studied, our work included
about 23% of them. There are patients that do not
adapt to the DC regimen, such as consultation peri-
odicity and participation in the weekly groups of DM
education.
In the period of the study (1 year), there were a
significant proportion of patients with desirable meta-
bolic control in the test group, despite the fact that all
patients (due to a limitation of basic resources, like
fast-acting insulin and dipsticks for self-management
supply) were treated with conventional insulin therapy
Table 1. Characteristics of patients in the test and control groups after one year.
Test Group (n= 175) Control Group (n= 30) p value
Age (years) 42.4 ± 14.2 42.6 ± 13.2 0.949
Gender (M/F) 83/92 13/17 0.698
Disease duration (years) 12.9 ± 9.2 12.5 ± 8.5 0.812
Age at DM onset (years) 29.4 ± 8.4 30.0 ± 12.0 0.721
FPG (mmol/l)* 9.6 ± 2.5 [9.1 to 10.1] 11.0 ± 1.6 [10.2 to 11.8] 0.003
A1C (%)* 7.28 ± 1.70 [6.94 to 7.61] 8.36 ± 1.07 [7.82 to 8.99] 0.001
NPH mean dose (U/kg/day)* 0.98 ± 0.47 1.23 ± 0.94 0.025
BMI (kg/m2) 27.3 ± 17.1 28.6 ± 4.4 0.679
Number of doses(1 dose/2 doses) 50/125 6/24 0.383
Dietary indiscretions* 42 13 0.043
Drug misuse 24 5 0.776
Hypoglycemic episodes 40 3 0.149
Ketoacidotic episodes 3 1 0.472
Number of consultations 6 up to 3 —
Data are n or mean ± SD. Values between brackets represent the 99% confidence interval.
*p< 5%. The factor used to convert mg/dl to mmol/l was 0.05551.
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(one or two daily applications of NPH). However,
similar reports exist both in national and international
literature (21,22). As our sample was composed by
adult T1DM patients, perhaps with a larger endoge-
nous insulin reserve (23), glycemic control may have
been facilitated. Data from a Belgian study of children
and adolescents using up to two daily insulin doses,
showed that 62% of the studied group reached a good
metabolic control (22), as well as demonstrated by
another Brazilian study (21).
The frequency of DC consultations (which was
bimonthly in our study), specialists care and a struc-
tured DM education service might have collaborated
in obtaining results with the use of conventional
insulin therapy (22,24).
This approach with one or two daily insulin
applications, for several reasons, is still frequently used
in several countries in the treatment of T1DM. A mul-
ticentric study (13) involving 18 countries showed
that 60% of the T1DM patients were in the regimen of
two daily insulin doses and 34% of them presented
good glycemic control — an inferior percentage in
comparison to our group and in the studies previous-
ly mentioned (21,22), perhaps because the analyzed
patients had not been assisted in structured DCs.
Anyway, regardless of the therapeutic modality
utilized, the percentage of patients that do not reach
the ideal metabolic control worldwide is still high even
with intensive insulin therapy, including developed
countries (10,24,25).
It is known that T1DM is a disease that requires
great commitment by patients to reach the desired
goals. The patients’ compliance is difficult to achieve,
perhaps providing an explanation for the difficulty in
getting the desired metabolic control, as mentioned
above.
It is plausible to presume that the multidiscipli-
nary team’s effort for improving the patients’ adher-
ence explain the relatively high amount of patients
with better metabolic control at the DC (26).
In regards to the ideal metabolic control (A1C
up to 7%), 51.4% of the patients assisted at the DC
reached such goal, versus only 16.7% in the control
group. In addition, it was statistically confirmed that
the patients assisted at the DC presented a likelihood
4.38 times higher of reaching levels of A1C up to 7%.
The characteristics of the patients studied, such
as gender, duration of the disease, age at the onset of
the disease, mean dose of insulin used and BMI do not
differ from other national (27-29) and international
(5) studies. Given a more advanced age of our
patients, it is possible that some of them presented
LADA, although patients with LADA sometimes do
not require insulin at diagnosis (30).
The T1DM diagnosis could not be confirmed
with laboratorial methods, since autoantibody mea-
surement was not available where the study was carried
out; furthermore nowadays the precise diagnosis of
T1DM is far from straightforward (2,31-34).
Table 2. Characteristics of patients in the test group, according to the A1C interval after one year.
Subgroup A (n= 90)  Subgroup B (n= 38)  Subgroup C (n= 47)  p value
A1C < 7.0% A1C: 7.1% to 8.0%  A1C > 8.0%
Age (years) 41.7 ± 13.7 41.2 ± 14.6 44.6 ± 14.8 0.459
Gender (M/F) 45/45 19/19 19/28 0.532
Disease duration (years) 12.5 ± 8.9 12.6 ± 9.7 14.2 ± 9.4 0.595
Age at DM onset (years) 29.2 ± 8.3 28.6 ± 8.2 30.4 ± 8.9 0.596
NPH mean dose (U/kg/day) 0.95 ± 0.46 1.10 ± 0.42 1.04 ± 0.5 0.211
BMI (kg/m2) 27.8 ± 23.1 26.0 ± 5.9 27.2 ± 6.4 0.855
Number of doses (1 dose/2 doses)* 32/58 4/34 14/33 0.016
Dietary indiscretions 22 7 13 0.606
Drug misuse 13 8 3 0.142
FPG (mmol/l)* 7.7 ± 1.0 10.0 ± 0.4 13.1 ± 1.7 0.001
Hypoglycemic episodes 23 7 10 0.650
Ketoacidotic episodes* 0 3 0 0.006
Data are n or mean ± SD. *p< 5%.
Figure 1. Patients’ proportions according to the A1C level
subgroups in the test group (n= 175) and in the control
group (n= 30).
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In the test group, the patients with worse meta-
bolic control used two insulin applications more fre-
quently than the group with better control. It is prob-
able that the option of changing from one to two
applications had been based on this criterion.
Although a study accomplished in Belgium demon-
strated no difference in the metabolic control of
patients using insulin two or four times a day (22).
The number of reports of dietary indiscretions
and drug misuse was equivalent in the three studied
subgroups of the test group. In the control group,
there were more dietary indiscretions, showing fewer
adherences of these patients.
There were 43 hypoglycemia reports in our
sample without the need of help from others for the
patients’ recovery. In fact, the studies show that the
frequency of serious hypoglycemia is directly related to
intensive glycemic control (5,35).
The four episodes of reported ketoacidosis
occurred in patients due to omission of insulin use.
Anyway, 26.9% of the patients of the test group
maintained levels of A1C above 8%. Besides the possi-
bilities discussed above, it is probable that the simulta-
neous use of fast-acting insulin and self-management
could improve this situation. Accordingly to Almeida
et al. (29), in Latin America only Brazil, Cuba and
Costa Rica distribute insulin gratuitously, and only
Costa Rica, among 12 studied countries, supplies nec-
essary material for the patients’ self-management.
Several limitations of our study must be consid-
ered concerning the generalization of our results. We
studied adult T1DM with a probably better insulin
reserve, our patients were very adherent to the pro-
ceedings of the DC and we carried out a historical
cohort analysis (in the future prospective clinical trials
may assess our results).
Besides, in our study it is possible that mild
hypoglycemia episodes may have occurred and this fact
could be related to the found A1C levels, although in
the control group the mean dose of NPH insulin was
larger. We could not evaluate this fact due to the lack
of self-management of the capillary glycemia.
Probably the chief fact that could explain our
relatively good results concerning the glycemic control
is that all the patients were completely adherent to the
DC rules, furthermore other studies showed that when
the therapeutic strategies are very complex, they can
impair the patients’ adherence (36,37).
To sum up, this study demonstrated that
patients attended by a structured multidisciplinary
team, with emphasis on the patient’s education with
good adherence, continuous supply of insulin, were
capable of reaching satisfactory results even without
resources for self-management of the glycemia and
using only NPH insulin, evidencing that in developing
countries it is possible to improve the patients’
glycemic control even when intensive insulin therapy is
not available.
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